CURRICULUM VITAE

Joann M. Berenda, AAB, CCRC

Chief Operating Officer
North Star Medical Research, LLC

18660 Bagley Road,
Building II, Suite 205
Middleburg Heights, OH 44130

Telephone: +01 440 234 5700
Fax: +01 440 234 5710
email: jberenda@northstarresearch.org

EDUCATION:

Cuyahoga Community College
Associate Degree of Applied Business Management

POSITIONS:

2007 – Present *North Star Medical Research, LLC*
Chief Operating Officer
Independent Medical Research

2006 – 2007 *Cleveland Neuro-Sleep Research Institute, Inc.*
Controller
Independent Medical Research

2006 – 2007 *MIR Imaging*
Operations Manager/Controller
Infrared Medical Imaging

1999-2006 *Health Design*
Operations Manager/Controller
Medical Manufacturer & Distributor

TRAINING & PROFESSIONAL MEMBERSHIPS:

- Certified Clinical Research Coordinator (CCRC)
- Association for Clinical Research Professionals (ACRP)
- MAGI Member
- Drug Information Association Member (DIA)
- Human Participant Protection Education for Research Teams
- IATA Certified – Handling of Biological Substances
- Certified in EDC Entry
- Trained in ECG Acquisition
- Good Clinical Practice (GCP)
- Administration of the Columbia-Suicide Severity Rating Scale (CSSR-S)
- Council of Smaller Enterprises (COSE), Planning Committee
- Blood Borne Pathogens
- Health Insurance & Privacy Accountability Act (HIPAA)
- Illegal Substance Supervisor Training
- Alcohol In The Workplace

INDUSTRY SPONSORED RESEARCH

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of NBI-98854 in Pediatric Subjects with Tourette syndrome.

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of NBI-98854 in Adult Subjects with Tourette Syndrome

A randomized, double-blind, placebo-controlled, clinical trial of structured opioid discontinuation versus continued opioid therapy in suboptimal and optimal responders to high-dose long-term opioid analgesic therapy for chronic pain.

A phase III, randomized, double-blind, active-controlled, parallel group, multi-center trial assessing the efficacy and safety of a once-weekly and once-monthly, long-acting subcutaneous injectable depot of Buprenorphine (CAM2038) in treatment of adult outpatients with Opioid Use Disorder.

Interventional, randomized, double-blind, placebo controlled, active reference (fluoxetine), fixed dose study of Vortioxetine in pediatric patients aged 7 to 11 years, with Major Depressive Disorder (MDD)

Interventional, randomized, double-blind, placebo controlled, active reference (fluoxetine), fixed dose study of Vortioxetine in pediatric patients aged 12 to 17 years, with Major Depressive Disorder (MDD)

Second phase 3 randomized, 12-week, double-blind, placebo-controlled study of the safety of Plecanatide in patients with Irritable Bowel Syndrome with Constipation (IBS-C).

An open-label, long-term safety and tolerability study of Plecanatide in patients with Irritable Bowel Syndrome with Constipation (IBS-C)

A 12-week, randomized, double-blind, parallel-group, placebo-controlled, flexibility-dosed, multicenter study to evaluate the efficacy, safety and tolerability of Dasotraline in adults with moderate to severe Binge Eating Disorder.

An open-label, flexibly-dosed, 6 month extension study of Dasotraline in the treatment of adults with Binge Eating Disorder.

A phase 3 study to evaluate weight gain ALK3831 compared to Olanzapine in adults with Schizophrenia.

A retrospective chart review study in patients that have been prescribed a pharmacogenomics test to perform research on the utilization, effectiveness and outcomes related to test results.

A prospective evaluation of treatment satisfaction with Buprenorphine/Naloxone Buccal Film (BBN) in opioid dependent subjects.

A phase III, double-blind, randomized, multicenter, placebo-controlled study to evaluate the efficacy and safety of TNX-102 SL tablets taken daily at bedtime in patients with fibromyalgia.

A phase 3, 3-month, multicenter, open-label extension study to evaluate the safety and efficacy of TNX-102 SL tablets taken daily at bedtime in patients with fibromyalgia.

A 6- week, randomized, double-blind, multicenter, placebo-controlled, parallel group efficacy and safety study of Dasotraline versus placebo in subjects 6 to 12 years of age with Attention Deficit Hyperactivity Disorder (ADHD).

An open-label, flexibly-dosed, 26 week extension safety study of Dasotraline in children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD)

A randomized, double-blind trial investigating the efficacy and safety of investigational medicinal product (IMP) in subjects with complex regional pain syndrome type I (CRPS-I)

Retrospective Registry exposure for: Various Disease States

A phase 3 Efficacy & Safety study of ALKS5461 for the adjunctive treatment of Major Depressive Disorder.

A phase 3 multicenter study of the long-term safety and tolerability of ALKS5461 for the adjunctive treatment of Major Depressive Disorder in adults who have an inadequate response to antidepressant therapy.

A national, randomized 12-week, double-blind, placebo-controlled study to assess the safety and efficacy of Plecanatide (3.0 and 6.0 mg) in patients with Chronic Idiopathic Constipation.

A multicenter, randomized, double-blind, placebo controlled, Fluoxetine-referenced, parallel group study to evaluate the efficacy, safety and tolerability of Desvenlafaxine Succinate Sustained Release (DVS SR) in the treatment of children and adolescents outpatients with Major Depressive Disorder.

A six month, open label, multi-center, flexible dose extension study to the B2061014 study to evaluate the safety, tolerability and efficacy of Desvenlafaxine Succinate Sustained Release (DVS SR) tablets in the treatment of children and adolescent outpatients with Major Depressive Disorder.

A randomized double-blind, placebo and active-controlled study of DS-5565-A-310 in subjects with pain associated with Fibromyalgia.

An open-label extension study of DS-5565-A-312 for 52 weeks in pain associated with Fibromyalgia.

A phase II, multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate efficacy and safety of XXX in combination with selective serotonin reuptake inhibitors in patients with Obsessive Compulsive Disorder.

A phase 2b, double-blind, randomized, multicenter, placebo-controlled study to evaluate the efficacy and safety of XXX tablets taken at bedtime in patients with Fibromyalgia.

A 12-month, Multicenter, Open-Label Extension (F203) study to evaluate the long-term safety of TNX-102 tablets taken daily at bedtime in patients with fibromyalgia.

A randomized, placebo-controlled study to investigate the efficacy and safety of Circadian to alleviate sleep disturbances in children with Neurodevelopmental Disabilities.

A multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of fixed-dose once-daily oral Aripiprazole in children and adolescents with Tourette's Disorder.

An open-label, multicenter study evaluating the safety and tolerability of once-daily oral Aripiprazole in children and adolescents with Tourette's Disorder.

A phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled, dose-optimization study to evaluate the efficacy, safety, and tolerability of study drug in adults aged 18-55 years with moderate to severe Binge Eating Disorder (BED).

A phase 3, multicenter, open label, 12 month extension safety and tolerability study of XXX in the treatment of adults with Binge Eating Disorder.

A phase 2, randomized, double-blind, placebo-controlled, does titration study to assess the safety and tolerability and efficacy of study drug for the treatment of Tardive Dyskinesia.

A randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy, safety and tolerability of study drug in the treatment of patients with diarrhea-predominant Irritable Bowel Syndrome (IBS-D).

A randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study to compare the efficacy, tolerability, and safety of 3 doses of gabapentin enacarbil (GSK 1838262) with placebo in the treatment of subjects with moderate-to-severe primary Restless Legs Syndrome (RLS).

A phase 2, randomized, double-blind, placebo-controlled, multicenter study to assess the safety and tolerability of SPD503 in subjects aged 6-17 years with Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SOP).

Pipamperone/Citalopram (PNB01) versus Citalopram (cit) and versus Pipamperone in moderate to severe Major Depressive Disorder (MDD): a randomized, double-blind phase iii clinical trial of 10 weeks.

A multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of flexible-dose once-weekly oral Aripiprazole in children and adolescents with Tourette's Disorder.

An open-label, multicenter study evaluating the safety and tolerability of once weekly oral aripiprazole in children and adolescents with Tourette's Disorder.

Antidepressant-induced sleepiness, cognitive symptoms and/or fatigue during SSRI treatment of Major Depressive Disorder (MDD).

A phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled, flexible dose titration, efficacy and safety study of SPD489 in combination with an antidepressant in the treatment of adults with Major Depressive Disorder (MDD) with inadequate response to prospective treatment with an antidepressant.

A phase 3, open-label, multicenter, 12-month extension safety and tolerability study of SPD489 in combination with an antidepressant in the treatment of adults with Major Depressive Disorder (MDD) with residual symptoms or inadequate response following treatment with an antidepressant.

A double-blind, Paroxetine- and placebo-controlled study of 50 mg/day and 100 mg/day of eb-1010 among outpatients with Major Depressive Disorder (MDD) who have responded inadequately to prior selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) (triple reuptake inhibitor anti-depressant effects – TRIADE study).

A randomized, double-blind, placebo-controlled, parallel-group, assessment of the efficacy, safety and tolerability of XX modified release tablets, 125 mg twice per day in subject with treatment resistant Depression.

Effect of Duloxetine 30/60 mg once daily versus placebo in adolescents with juvenile Primary Fibromyalgia Syndrome.

A multicenter, randomized, double-blind, placebo-controlled withdrawal study to evaluate the safety, tolerability, and efficacy of Milnacipran in pediatric patients with Primary Fibromyalgia.

A multicenter, open-label, 52-week extension study to evaluate the safety and efficacy of Milnacipran in pediatric patients with Primary Fibromyalgia.

A randomized, placebo-controlled, double-blind study of ly2216684 fixed-dose 12 mg and 18 mg once daily as adjunctive treatment for patients with Major Depressive Disorder (MDD) who are partial responders to selective serotonin reuptake inhibitor (SNRI) treatment.

A multicenter, randomized, placebo-controlled, double-blind study of the efficacy and safety of Lubiprostone in subjects with Opioid-Induced Bowel Dysfunction.

A multicenter, randomized, double-blind, parallel group, placebo-controlled, phase 3, efficacy and safety study of TC-5214 (S-Mecamylamine) in flexible doses as an adjunct to an antidepressant in patients with Major Depressive Disorder (MDD) with an inadequate response to antidepressant therapy (FLEX).

A multicenter, randomized, double-blind, parallel group, placebo-controlled, phase 3, long-term safety and tolerability study of TC-5214 (S-Mecamylamine) as an adjunct to an antidepressant in patients with Major Depressive Disorder who exhibit an inadequate response to antidepressant therapy (LTS).

A 52-week, multi-center, open-label study of the safety and tolerability of Agomelitine sublingual tablets in patients with Major Depressive Disorder (MDD).

A phase 3, randomized, double-blind, parallel-group, placebo-controlled, fixed-dose study comparing the efficacy and safety of 2 doses (10 and 20 mg) of LuAA21004 in acute treatment of adults with Major Depressive Disorder (MDD).

A phase 3, long-term, open-label, flexible dose, extension study evaluating the safety and tolerability of LuAA21004 (15 and 20 mg) in subjects with Major Depressive Disorder (MDD).

A fifteen-month, prospective, randomized, active-controlled, open-label, flexible-dose study of Paliperidone Palmitate compared with oral antipsychotic treatment in delaying time to treatment failure in adults with Schizophrenia who have been recently released from jail.

A phase 3b multicenter, double-blind, randomized withdrawal efficacy and safety study of Pregabalin in the treatment of patients with inadequately treated painful Diabetic Peripheral Neuropathy (DPN).

A long-term, open label, safety of XX in children (6 to 11 years) and adolescents (12 to 17 years) with Attention Deficit/Hyperactivity Disorder-Associated Insomnia.

A double-blind, efficacy and safety study of duloxetine versus placebo in the treatment of children and adolescents with Major Depressive Disorder (MDD).

A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of Armodafinil treatment (150 mg) in improving clinical condition late in the shift and in improving functional and patient-reported outcomes in adult patients with excessive sleepiness associated with Shift Work Disorder.

A phase 2b, randomized, double-blind, two-arm, multi-center, placebo-controlled, study to assess the efficacy and safety of EN3224 (Axomadol) in subjects with moderate to severe Chronic Low Back Pain.

A prospective, randomized, active-controlled, rater-blinded study of the prevention of relapse comparing Paliperidone Palmitate with oral Risperidone in adults with recently-diagnosed Schizophrenia who are at high risk of relapse.

A phase 2, multicenter, randomized, double-blind, parallel group, placebo-controlled exploratory efficacy and safety study of SPD489 in adults 18-55 years with Major Depressive Disorder (MDD) as augmentation therapy to an antidepressant.

A 12 week, randomized, double-blind, placebo-controlled, parallel-group, fixed dosage, study to evaluate the efficacy and safety of Armodafinil as treatment for patients with excessive sleepiness associated with mild or moderate closed Traumatic Brain Injury (TBI).

A phase 2, multicenter, randomized, double-blind, placebo-controlled study of the safety and efficacy of OPC-34712 as adjunctive therapy in the treatment of patients with Major Depressive Disorder (MDD).

Continuation Study – A phase II, multicenter, open-label study to assess the safety and tolerability of oral OPC-34712 as adjunctive therapy in adult patients with Major Depressive Disorder (MDD).

A 52-week, multicenter, open-label study to evaluate the effectiveness of Aripiprazole intramuscular depot as maintenance treatment in patients with Schizophrenia "ASPIRE open-label" (**A**ripiprazole intramu**s**cular de**p**ot program **i**n Schizoph**re**nia)."

A multi-center, randomized, placebo-controlled, double-blind, parallel group, efficacy and safety study of AZD7325 in the treatment of Generalized Anxiety Disorder (GAD).

A 3-arm, double-blind, placebo controlled clinical trial to assess the efficacy, safety and tolerability of Pagoclone for the adult treatment of adults with Stuttering.

A randomized double blind placebo controlled four week study of the efficacy and safety of four doses (0.05 mg, 0.1 mg, 0.25 mg, 0.5 mg) of Aplindore MR tablets vs. placebo in idiopathic Restless Legs Syndrome (RLS).

A phase III, double-blind, randomized, efficacy and safety study comparing the TAK-491 plus Chlorthalidone fixed dose combination vs Benicar HCT® (Olmesartan Medoxomil-Hydrochlorothiazide) in subjects with moderate to severe essential Hypertension (HPTN).

A randomized, double-blind, parallel-group, placebo controlled, duloxetine-referenced, fixed dose study comparing the efficacy and safety of LuAA21004 in acute treatment of Major Depressive Disorder (MDD) in elderly patients.

A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Armodafinil at a target dosage of 200 mg/day as treatment for adults with excessive sleepiness associated with Obstructive Sleep Apnea/Hypopnea Syndrome (OSA) with comorbid Major Depressive Disorder (MDD) or Dysthymic Disorder.

A randomized, double-blind, placebo-controlled subjective study to access the efficacy of APD125 in patients with primary Insomnia characterized by difficulty maintaining sleep.

A randomized, double-blind, parallel-group, placebo-controlled, fixed dose study comparing the efficacy and safety of 2 doses of LuAA21004 in acute treatment of adults with Generalized Anxiety Disorder (GAD).

A double-blind, randomized, placebo and active-controlled, multi-center study examining the efficacy and safety of SEP-225441 in subjects with Generalized Anxiety Disorder (GAD).

A year-long, open-label, multicenter study of the safety and efficacy of vilazodone in subjects with Major Depressive Disorder (MDD).

A multicenter, double-blind, randomized, placebo-controlled study examining the safety, efficacy, and tolerability of SEP-225289 in subjects with Major Depressive Disorder (MDD) (including atypical and melancholic features).

A multicenter, multiple dose, double-blind, randomized, placebo-controlled, parallel group study of the safety and efficacy of AGN 203818 in female patients with Fibromyalgia Syndrome.